Literature DB >> 17728140

Antidepressants induce cellular insulin resistance by activation of IRS-1 kinases.

Yechiel Levkovitz1, Galit Ben-Shushan, Avia Hershkovitz, Roi Isaac, Irit Gil-Ad, Dima Shvartsman, Denise Ronen, Abraham Weizman, Yehiel Zick.   

Abstract

Certain selective serotonin reuptake inhibitors (SSRIs) induce the clinical and biochemical manifestations of a metabolic syndrome by as yet unknown mechanism. Here we demonstrate that incubation (1 h) of rat hepatoma Fao cells with the SSRIs paroxetine and sertraline, but not with the atypical antipsychotic drug olanzapine, inhibited the insulin-stimulated Tyr phosphorylation of the insulin receptor substrate-1 (IRS-1) with half-maximal effects at approximately 10 microM. This inhibition correlated with a rapid phosphorylation and activation of a number of Ser/Thr IRS-1 kinases including JNK, S6K1, ERK and p38 MAPK, but not PKB (Akt). JNK appears as a key player activated by SSRIs because specific JNK inhibitors partially eliminated the effects of these drugs. The SSRIs induced the phosphorylation of IRS-1 on S307 and S408, which inhibits IRS-1 function and insulin signaling. These results implicate selected SSRIs as inhibitors of insulin signaling and as potential inducers of cellular insulin resistance.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17728140     DOI: 10.1016/j.mcn.2007.05.009

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  23 in total

1.  The antidepressant sertraline targets intracellular vesiculogenic membranes in yeast.

Authors:  Meredith M Rainey; Daniel Korostyshevsky; Sean Lee; Ethan O Perlstein
Journal:  Genetics       Date:  2010-05-10       Impact factor: 4.562

Review 2.  JNK: a stress-activated protein kinase therapeutic strategies and involvement in Alzheimer's and various neurodegenerative abnormalities.

Authors:  Sidharth Mehan; Harikesh Meena; Deepak Sharma; Rameshwar Sankhla
Journal:  J Mol Neurosci       Date:  2010-09-28       Impact factor: 3.444

3.  Insulin and metabolic stress stimulate multisite serine/threonine phosphorylation of insulin receptor substrate 1 and inhibit tyrosine phosphorylation.

Authors:  Nancy J Hançer; Wei Qiu; Christine Cherella; Yedan Li; Kyle D Copps; Morris F White
Journal:  J Biol Chem       Date:  2014-03-20       Impact factor: 5.157

4.  Use of antidepressant medication and risk of type 2 diabetes: results from three cohorts of US adults.

Authors:  A Pan; Q Sun; O I Okereke; K M Rexrode; R R Rubin; M Lucas; W C Willett; J E Manson; F B Hu
Journal:  Diabetologia       Date:  2011-08-03       Impact factor: 10.122

5.  High-fat diet-induced metabolic disorders impairs 5-HT function and anxiety-like behavior in mice.

Authors:  Juliane Zemdegs; Gaël Quesseveur; David Jarriault; Luc Pénicaud; Xavier Fioramonti; Bruno P Guiard
Journal:  Br J Pharmacol       Date:  2015-12-09       Impact factor: 8.739

Review 6.  Glucose dysregulation associated with antidepressant agents: an analysis of 17 published case reports.

Authors:  Star Khoza; Jamie C Barner
Journal:  Int J Clin Pharm       Date:  2011-04-13

7.  Selective serotonin reuptake inhibitors (SSRIs) inhibit insulin secretion and action in pancreatic β cells.

Authors:  Roi Isaac; Sigalit Boura-Halfon; Diana Gurevitch; Alla Shainskaya; Yechiel Levkovitz; Yehiel Zick
Journal:  J Biol Chem       Date:  2012-12-28       Impact factor: 5.157

8.  Use of antidepressant agents and the risk of type 2 diabetes.

Authors:  S Khoza; J C Barner; T M Bohman; K Rascati; K Lawson; J P Wilson
Journal:  Eur J Clin Pharmacol       Date:  2011-11-26       Impact factor: 2.953

9.  Weight and metabolic effects of dietary weight loss and exercise interventions in postmenopausal antidepressant medication users and non-users: a randomized controlled trial.

Authors:  Ikuyo Imayama; Catherine M Alfano; Caitlin Mason; Chiachi Wang; Catherine Duggan; Kristin L Campbell; Angela Kong; Karen E Foster-Schubert; George L Blackburn; Ching-Yun Wang; Anne McTiernan
Journal:  Prev Med       Date:  2013-07-13       Impact factor: 4.018

10.  The selective serotonin reuptake inhibitor sertraline enhances counterregulatory responses to hypoglycemia.

Authors:  Nicole M Sanders; Charles W Wilkinson; Gerald J Taborsky; Salwa Al-Noori; Wendi Daumen; Aryana Zavosh; Dianne P Figlewicz
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-03-11       Impact factor: 4.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.